Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites.

ABSTRACT: Introduction: The polymorphic enzyme cytochrome P450 2D6 (CYP2D6) catalyzes a major step in the bioactivation of tamoxifen. Genotyping of clinically relevant CYP2D6 alleles and subsequent dose adjustment is a promising approach to individualize breast cancer therapy. The aim of this study was to investigate the relationship between the plasma levels of tamoxifen and its metabolites and different CYP2D6 genotypes under standard (20 mg/day) and dose-adjusted therapy (Registration ID in Iranian Registry of Clinical Trials: IRCT2015082323734N1). Materials and Methods: Using TaqMan^® assays common alleles of CYP2D6 (^∗1, ^∗2, ^∗4, ^∗5, ^∗6, ^∗10, ^∗17, and ^∗41) and gene

SUBMITTER: Khalaj Z 

PROVIDER: S-EPMC6543868 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature